GlassScriptPhysician profile
Brittany Kable
NPI 1538642715
$1,633.05
in general payments reported to CMS, 2019-2025
11 companies · $597 in 2025
The $597 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $309 · 2022: $162 · 2023: $118 · 2024: $448 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,162.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $588.88 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $438.57 | 2021-2022 | |
| Abbvie INC. | $340.48 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $89.35 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $35.99 | 2024 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.05 | 2024-2025 | Xifaxan |
| Janssen Biotech, INC. | $25.03 | 2023 | Stelara |
| Genzyme Corporation | $22.24 | 2024 | |
| Intercept Pharmaceuticals, INC. | $21.33 | 2024 | |
| Novo Nordisk INC | $20.80 | 2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $20.33 | 2024 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Kable listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.